Thus, both assessment of hyperbilirubinemia and UGT1A genotyping will be useful for complementing toxicity risk profiling and optimizing risk-adapted therapeutic strategies for pediatric ALL. The gene discussed is UGT1A1; the disease is acute lymphoblastic leukemia.